TMEM33

Across TCGA pan-cancer cohorts, TMEM33 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM33 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM33 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM33 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where TMEM33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.455	0.788	.004	18	view →
CCRCC	DFS	Quartile	All	0.907	0.592	.009	9	view →
LSCC	DFS	Quartile	III,IV	0.345	0.875	.018	8	view →
HNSC	OS	Median	All	0.940	0.773	.012	7	view →
GBM	DFS	Quartile	All	0.223	0.519	.042	5	view →
PDAC	OS	Tertile	All	0.459	0.667	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM33–LUAD (DFS)

Open the LUAD breakdown →